CClinicalTrials.gg
RecruitingNCT07577947HARMONYUpdated Jul 6, 2026

Health And Response: Digital Markers for Outcomes in Perinatal Depression Treatment Study

An interventional study of Perinatal depression online cognitive-behavioral therapy course and Clinical care (psychotherapy sessions) in Depression and Perinatal Depression, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Other

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to determine if the addition of digital sensing data collected from phones and watches during the early stages of perinatal depression (PND) treatment can better predict treatment outcomes than using self-reported symptoms alone.STAND for PND: The UCLA Depression Grand Challenge (DGC) has previously developed a technology-assisted, scalable therapy system called STAND (Screening and Treatment for ANxiety and Depression) for perinatal depression (PND) and has demonstrated in an initial randomized clinical trial that this treatment intervention to be as effective as psychiatrist delivered care for PND. In this study, the investigators will administer STAND for PND for up to 12 weeks as part of study participation. There will be no comparison between our treatment intervention and a treatment as usual condition, as this is not a trial of efficacy. In the STAND for PND treatment model, women with moderate symptoms will be routed to coach-guided, digital cognitive behavioral therapy (CBT) tailored to PND, which has been demonstrated to be an effective treatment approach for PND. Women with severe depression or suicidality will be routed to clinician delivered CBT, with pharmacotherapy as needed, with both CBT and pharmacotherapy demonstrated to be effective treatment approaches for PND. Symptoms will be regularly monitored throughout the intervention period. Digital Sensing in Depression: The DGC also has substantial experience in large-scale longitudinal digital sensing studies, and experience identifying associations between self-report or clinical ratings of depressive symptoms and digital sensing features, including in pregnant and postpartum women. Digital Sensing in a STAND for PND study: In our previous STAND for PND study, the investigators did not include digital sensing. In this next phase of our research program, the investigators will collect digital sensing data from phones and watches during the first four weeks of study participation. The investigators will enroll up to 250 women during their last trimester or who are in the postpartum period to participate in the 12-week study, which includes treatment provided through the STAND for PND program of care and during which the investigators will obtain 4-weeks of digital sensing data.The investigators will be testing whether behaviors measures through digital sensing (i.e., digital features) in combination with self-reported depression symptoms will better predict treatment outcomes than the self-reported depression symptoms alone. The investigators are testing the hypothesis that prospective longitudinal assessments using digital devices will enhance our ability to predict outcomes of STAND-PND.This project is part of a larger program of research that aims to improve clinical decision-making for PND by establishing a clinical care model for PND that fully integrates digital sensing with digital therapy. An additional objective of this program of research is to target low-income mothers from populations that have had limited access to mental healthcare, given that this population is particularly vulnerable to the impact of PND.

02

Conditions studied

  • Depression
  • Perinatal Depression

Browse trials for

Keywords

  • depression
  • perinatal depression
03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's planned enrollment of 250 is above the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • At least 18 years of age
  • Able to read and communicate in English
  • Between 28 weeks pregnant and 12 weeks postpartum
  • Moderate-to-severe depression, as defined by Edinburgh Postnatal Depression Scale (EPDS) score ≥11
  • Not currently seeing a provider for mental health care
  • Own functioning iOS smartphone (iPhone 11 or newer, iOS 18 or newer) with access to reliable data plan and Wifi)
  • Able to read and understand a written informed consent form
  • Willingness to participate in treatment through the study and follow all study procedures, including providing HIPAA Authorization for research, installing a study app on personal iPhone, and wearing the provided Apple Watch for at least 20 hours every day in the first four weeks of the study (including while sleeping)

Exclusion criteria

Exclusion Criteria:

  • Currently receiving treatment by a therapist or a psychiatrist
  • Unstable suicidality (e.g., 2 or more suicide attempts or self-injurious behaviors resulting in hospitalization in the last 6 months)
  • Current substance use disorder that interferes with treatment: specifically, patients meeting diagnostic criteria for Substance Use Disorder (SUD) will be eligible for inclusion only if they are able to attend sessions while not under the influence of that substance, with the exception of individuals abusing opiates or freebase cocaine, who will be excluded
  • Principal diagnosis of psychosis unrelated to depression (unipolar or bipolar)
  • Neurological conditions
  • Severe uncontrolled medical conditions (e.g., anorexia nervosa, cardiac conditions requiring continuous monitoring)
  • Cognitive impairment (e.g., developmental disability, dementia)
  • Previously participated in the UCLA Depression Grand Challenge "New Moms Mood Tracking \& Wellbeing Study" (IRB #20-001924)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Tier 2 - PND Digital Therapy with Coaching

    Participants with a recent EPDS score in the moderate range (11-18) and no current suicidality will be given access to a perinatal depression online cognitive-behavioral therapy course (the ParentMood program). Some of the lesson content is presented as illustrated videos. Following each lesson, participants can download a document that summarizes the key information in each lesson, and which includes practical homework exercises that reinforce the content of the lesson. Participants are encouraged to practice their lesson homework for at least one week before starting the next lesson. Lessons will be completed sequentially. Participants have the option of accessing the content through a web-browser. Participants may receive up to 9 coaching sessions with their assigned Coach, in addition to an initial Orientation session, which will occur through secure video conference. The initial Orientation session is required, but the additional coaching sessions thereafter are optional.

    Behavioral: Perinatal depression online cognitive-behavioral therapy course

  • Active comparator
    Tier 3 - Clinical Care

    Participants with a recent EPDS score in the severe range (19-30) and/or significant suicidality with intent or means will be given access to a clinical care, which entails weekly psychotherapy sessions. The number and schedule of psychotherapy sessions in the study is determined by the clinical care team. Treatment appointments will occur through secure video conference. If the clinical team believes that consultation with a psychiatrist is warranted, a referral will be made to a UCLA Health clinic (e.g., the MOMS Clinic) for a consultation session and possible pharmacotherapy.

    Behavioral: Clinical care (psychotherapy sessions)

Interventions

  • BehavioralPerinatal depression online cognitive-behavioral therapy course

    Participants with a recent EPDS score in the moderate range (11-18) and no current suicidality will be given access to a perinatal depression online cognitive-behavioral therapy course (the ParentMood program). Some of the lesson content is presented as illustrated videos. Following each lesson, participants can download a document that summarizes the key information in each lesson, and which includes practical homework exercises that reinforce the content of the lesson. Participants are encouraged to practice their lesson homework for at least one week before starting the next lesson. Lessons will be completed sequentially. Participants have the option of accessing the content through a web-browser. Participants may receive up to 9 coaching sessions with their assigned Coach, in addition to an initial Orientation session, which will occur through secure video conference. The initial Orientation session is required, but the additional coaching sessions thereafter are optional.

  • BehavioralClinical care (psychotherapy sessions)

    Participants with a recent EPDS score in the severe range (19-30) and/or significant suicidality with intent or means will be given access to a clinical care, which entails weekly psychotherapy sessions. The number and schedule of psychotherapy sessions in the study is determined by the clinical care team. Treatment appointments will occur through secure video conference. If the clinical team believes that consultation with a psychiatrist is warranted, a referral will be made to a UCLA Health clinic (e.g., the MOMS Clinic) for a consultation session and possible pharmacotherapy.

06

What researchers measure

Primary outcomes

  1. Edinburgh Postnatal Depression Scale (EPDS) total score

    Self-reported depression symptom severity scores

    Time frame: From enrollment through the twelve weeks of the study.

  2. Percent change in EPDS scores

    Percent change in self-reported depression symptom severity scores (as measured with EPDS)

    Time frame: From enrollment through the twelve weeks of the study.

Secondary outcomes

  1. Treatment retention, as defined by number of coaching or therapy sessions attended by participants

    Measure of treatment retention, as defined by number of coaching or therapy sessions attended. A participant is considered to have been retained in treatment if they completed number of sessions advised by their therapist, or to have not been categorized as dropping from treatment early.

    Time frame: From week 2 through week 13 of the study

  2. Treatment retention, as defined by whether the participant completed treatment or not

    Measure of treatment retention, as defined by whether the participant completed treatment or not

    Time frame: From week 2 through week 13 of the study

07

Study locations

1 of 1 sites recruiting
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
    Recruiting
08

References and documents

Study documents

  • Study protocol · Dec 5, 2025
  • Informed consent form · Apr 16, 2026

Documents are hosted by the registry — open the source record to download them.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07577947
Lead sponsor
University of California, Los Angeles
Collaborators
Foundation for Women's Health
Responsible party
Michelle Craske (Distinguished Professor, University of California, Los Angeles) — Principal investigator
First posted
May 11, 2026
Start date
May 1, 2026
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Eliza Congdon, PhD
Contact
harmonystudy@mednet.ucla.edu
(310)-339-9053
Nelson Freimer, MD
principal investigator · University of California, Los Angeles
Michelle G Craske, PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion